Key Takeaways
- • TCG Crossover has raised $600m for its first dedicated Asian life sciences fund.
- • The fund marks the firm's expansion beyond its established US and European investment strategies.
- • The firm is opening offices in Shanghai and Hong Kong to support its Asian biotechnology investment activity.
- • The raise signals sustained institutional appetite for biotechnology exposure in Asia.
Summary
TCG Crossover has raised $600m for its debut Asian life sciences fund, according to AltAssets. The vehicle marks the firm's first dedicated strategy focused on the region and extends its investment platform, which previously centred on the United States and Europe, into biotechnology innovation across Asia.
Alongside the close, TCG Crossover is opening offices in Shanghai and Hong Kong. The reported details are limited to the publisher summary and headline; the full article is behind a paywall, so further information on the fund's target size, strategy, investment focus, and key personnel is not available in the source material.
Alongside the close, TCG Crossover is opening offices in Shanghai and Hong Kong. The reported details are limited to the publisher summary and headline; the full article is behind a paywall, so further information on the fund's target size, strategy, investment focus, and key personnel is not available in the source material.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.